SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to a heavy capital expenditure forecast for AI infrastructure that has sharply compressed free cash flow. While the company's advertising business continues to show solid revenue growth, the community is debating whether these aggressive AI investments will deliver long-term returns or continue to weigh on margins.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors digest a strong earnings report and the companys decision to maintain its capital expenditure forecast, which has successfully eased market anxieties regarding AI infrastructure spending. The community is actively debating the stock's role as a market stabilizer, with many highlighting Azure's cloud growth and Copilot adoption as key differentiators that distinguish Microsoft from other hyperscalers.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors debate whether the recent share price volatility represents a manipulation-driven pump-and-dump or a buying opportunity, given the company's QNX software integration in the automotive and robotics sectors. The community is actively tracking the upcoming August deadline for the Alloy Kore deal, while expressing intense frustration and suspicion over recent insider selling activity and management's silence during the current downward pressure.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the broad regulatory approval of Anktiva in the UAE, which serves as a significant milestone for the company's global expansion strategy. The community is actively debating the potential for this news to catalyze a short squeeze, while also expressing frustration over the lack of broader institutional partnerships and recent stock volatility.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The market is experiencing heightened volatility fueled by persistent Middle East tensions, mixed earnings from tech giants, and intense community debate over the Fed's future rate path. Traders are actively monitoring bond yields and key support levels while debating whether recent price swings represent a bottom or a setup for further downside.

BlackBerry is seeing intense discussion around its QNX software platform serving as a critical foundational layer for physical AI and robotics, following high-profile partnerships with major semiconductor leaders. While the stock experiences volatility from insider trading activity and short interest, investors are primarily focused on the upcoming Alloy Kore contract announcements as a key catalyst for long-term revenue growth.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

Semiconductor stocks are facing intense volatility as traders debate whether recent price swings represent a healthy consolidation amid continued massive AI infrastructure spending or the start of a deeper sector-wide correction. While market sentiment remains conflicted due to geopolitical tensions and concerns over capital expenditure sustainability, the community is actively tracking support levels and debating the viability of leveraged ETFs in the face of ongoing sector rotation.

SharonAI Holdings, Inc. operates as a holding company that develops and delivers GPU cloud computing and AI solutions. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings is capturing investor interest following a major multi-year cloud computing agreement that has energized the community's focus on its infrastructure-heavy business model. Traders are actively debating the company's valuation, institutional backing from significant market players, and the potential for a long-term supply squeeze given its low-float status and expanding compute capacity.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is facing significant volatility ahead of a pivotal Advisory Committee meeting and a PDUFA deadline as investors debate whether the company's resubmitted BLA and long-term survival data can overcome historical FDA concerns regarding trial design and efficacy. The community is actively discussing the stock's high binary risk, questioning the validity of the data, and speculating on whether the company faces another complete response letter or a breakthrough approval.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining traction as investors discuss its potential to capture significant market share in the brokerage sector, leading to active community debate regarding its valuation compared to industry peers. Market participants are closely watching technical levels and volume trends as bullish sentiment builds around recent platform enhancements and positive analyst updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 21, 2026 NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...

TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations

TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations...

TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch

Equity

Bank of America analyst Alec Stranahan raised his price target on TG Therapeutics to $20 from $17 but kept an ‘Underperform’ rating on the shares.


TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia

TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.

Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?

TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.read more...

TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data

Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug. 

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

TG Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TGTXTG Therapeutics Inc

Fundamentals

Latest TGTX News